Jennifer Green

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment

Vivian Barry-Hamilton, Rhyannon Spangler, Derek Marshall et al. · Nature Medicine · 2010 · 855 citations

Life Sciences, Biochemistry, Cell Biology +13

Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

Madhav V. Dhodapkar, Mario Sznol, Biwei Zhao et al. · Science Translational Medicine · 2014 · 357 citations

Life Sciences, Immunology, Clinical Immunology +10

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer

Denise A. Yardley, Robert Weaver, Michelle Melisko et al. · Journal of Clinical Oncology · 2015 · 189 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer

Johanna C. Bendell, Mansoor N. Saleh, April A. N. Rose et al. · Journal of Clinical Oncology · 2014 · 108 citations · Full text

Medicine, Oncology, Pharmacology +17